NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE **TECHNOLOGY APPRAISAL PROGRAMME**

Equality impact assessment – Scoping

STA Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]

The impact on equality has been assessed during this appraisal according to the

principles of the NICE Equality scheme.	
1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No potential equality issues have been identified during the scoping process.	
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
Not applicable.	
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
No changes have been made.	
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.	
Approved by Associate Director (name): Janet Robertson	

Date: 17 August 2021

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of tebentafusp for

treating advanced (unresectable or metastatic) uveal melanoma

Issue date: August 2021 1 of 1